苯肾上腺素O-芳基硫酸盐 | 1242184-39-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 中文名称: 苯肾上腺素O-芳基硫酸盐
• 英文名称: Phenylephrine-3-O-sulfate
• 英文别名: [3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenyl] hydrogen sulfate
• CAS: 1242184-39-9
• 化学式: C₉H₁₃NO₅S
• 分子量: 247.27
• InChiKey: RNPCQQLCTVIPNU-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• SELECTIVE METABOLIC APPROACH TO INCREASING ORAL BIOAVAILABILITY OF PHENYLEPHRINE AND OTHER PHENOLIC BIOACTIVITIES
  申请人：VIRGINIA COMMONWEALTH UNIVERSITY

  公开号：US20140221426A1

  公开（公告）日：2014-08-07

  Presystemic metabolism in intestine of bioactives such as phenylephrine is avoided by administering a subject (human or animal) the bioactive (e.g., phenylephrine) in combination with one or more inhibitors of sulfation (e.g., sulfotransferase enzymes aka SULTs). This can also be enhanced be co-administering inhibitors of monoamine oxidases aka, MAOs, and uridine diphosphate glucoronysl transferases, aka UGTs. Preferably the inhibitors are GRAS compounds. The one or more inhibitor compounds inhibit the enzymes responsible for rapid presystemic metabolism, thus allowing the bioactives (e.g., phenylephrine) to be more readily absorbed intact into the circulatory system.
• US20140271891A1
  申请人：——

  公开号：US20140271891A1

  公开（公告）日：2014-09-18
• US20140271892A1
  申请人：——

  公开号：US20140271892A1

  公开（公告）日：2014-09-18
• US20140271893A1
  申请人：——

  公开号：US20140271893A1

  公开（公告）日：2014-09-18
• PROCESS FOR MANUFACTURING PHENYLEPHRINE RESINATE PARTICLES PHENYLEPHRINE RESINATE PARTICLES AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONS
  申请人：JOHNSON & JOHNSON CONSUMER INC.

  公开号：US20160166518A1

  公开（公告）日：2016-06-16

  Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.